ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

March 25, 2008 09:00 ET

ALDA Develops, Tests and Submits Patent Application for New T36® Anti-Inflammatory, Antiseptic Therapeutic Formulation

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 25, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has filed a comprehensive new patent application under the Patent Cooperation Treaty (PCT). The new PCT application seeks protection for the composition and preparation of T36® formulations that also contain steroids, anesthetics or analgesics for use on topical infections and, in particular, inflamed infections. Typically, infections with associated inflammation are treated with separate antiseptic and anti-inflammatory preparations. The new T36® formulations combine these properties into a single treatment, making the prescription process easier for the physician and the application easier for the patient.

In preliminary studies under the direction of a physician, T36® formulations containing anti-inflammatory steroids quickly resolved a number of serious skin infections, some of which had resisted all other treatments. Examples include chronic eczema with secondary Staphylococcus infections and fungal infections, such as athlete's foot and Tinea versicolor.

Dr. Terrance Owen, President and CEO, states, "The ability of the new anti-inflammatory formulations to quickly resolve a wide variety of topical infections provides further verification of the effectiveness of the T36® technology. Clearly, we are very excited by these results because the new formulations open up therapeutic markets that we had not originally targeted. Even a superficial search of the markets for the treatment of eczema, athlete's foot, toenail infections and insect bites indicates that the market for these new formulations is very large and growing. We now plan on moving forward with the required testing of these products for topical infections as quickly as possible."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    or
    ALDA Pharmaceuticals Corp. - Distribution & Sales Contact
    Peter Chen
    CFO and Director
    (604) 521-8300 Ext. 3
    (604) 521-8322 (FAX)
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp. - Investor Relations Contact
    Scott Young
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com